Bioprocessing spotlight: Meet the Croda Pharma experts heading to BioProcess International Europe

As BioProcess International Europe in Vienna approaches this Spring, we’re excited to take part in the conversations around technologies, trends and meet the people translating science into progress.

Croda Pharma will be represented by two of our experts with hands on experience across bioprocessing, formulation, and biologics manufacturing: Geoff Platt, PhD and Chris Wells, who will be sharing insights shaped by real world development challenges and customer collaboration.

Introducing Geoff Platt and Chris Wells

Geoff Platt, PhD, Technology Specialist at Croda Pharma, has a strong background in protein chemistry and bioprocessing applications. With experience spanning academic research and industrial development, Geoff focuses on how materials behave within biological systems, ensuring science translates reliably into manufacturing reality.

Alongside him, Chris Wells, Applications Team Leader, brings expertise in amino acids in his role across bioprocessing and formulation workflows. His work centres on understanding how purity, consistency and selection of materials can influence process performance and final product quality.

Why BioProcess International Europe matters

With increasing productivity and efficiency now the number one strategic priority for bioprocessing in 2026, BioProcess International Europe continues to attract a global audience focused on practical approaches to efficiency and robustness across upstream, downstream and advanced therapy development. For us here at Croda Pharma, this event is about the conversations, meeting people, understanding their challenges, and exchanging ideas that carry on well beyond the event itself.

Croda Pharma in Vienna: A European first for BioXPro™

This year’s event also marks an important milestone. BioProcess International Europe will be the first time Croda Pharma presents BioXPro™ in Europe.

As regulatory expectations continue to increase, greater scrutiny is being placed on raw materials as key contributors to quality in bioprocessing. Agencies including the FDA, EMA and ICH now emphasise risk based assessment, traceability and control of raw materials, reflecting their direct impact on process robustness and product consistency.

BioXPro™ is our high purity amino acids platform, developed to meet these evolving demands, where we know consistency, control and confidence in raw materials matter.

Over the past month alone, four new BioXPro™ products have been added to the portfolio, reflecting its rapid expansion and growing relevance across bioprocessing and formulation applications.

Rather than focusing on specifications, the conversation in Vienna will centre on why material quality matters and how high purity inputs can help reduce variability, simplify development decisions and support more robust processes.

Supporting bioprocessing from challenge to control

Alongside BioXPro™, Croda Pharma will also be highlighting its broader bioprocessing portfolio, including solutions designed to support viral inactivation, cell culture protection and process robustness.

These tools are part of our philosophy: enabling bioprocessing teams to mitigate risk while scaling innovation, supported by materials designed with regulatory expectations, reproducibility and sustainability in mind.

Join the conversation in Vienna

If you’ll be attending BioProcess International Europe in Vienna, we’d love you to join us, meet Geoff and Chris, explore BioXPro™ for the first time in Europe, and be part of the conversations driving the next phase of bioprocessing.

Register and find out more about the event here: